ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Educational Symposium

IgA Nephropathy: Proteinuria, Vasoactive Peptides, and the Evolving Treatment Landscape

November 03, 2023 | 12:45 PM - 01:45 PM

Location: Grand Ballroom Salon A, Level 5, Philadelphia Marriott Downtown

Session Description

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and remains an important cause of progressive kidney disease and ESKD. The only validated prognostic serum or urine biomarkers for IgAN are eGFR and proteinuria. Proteinuria is the single strongest predictor of progression in IgAN, and remission of proteinuria has been found to substantially improve prognosis. Reduction of proteinuria to less than 1 g/day, and if possible <0.5 g/day, is a primary aim of therapy in IgAN. In contrast to many other forms of glomerular disease, optimization of supportive care, rather than immunosuppressive therapies, is the mainstay of treatment.

Inhibition of vasoactive peptides, such as angiotensin II, has been a staple of supportive care in IgAN. More recently, endothelin-1 (ET-1), another vasoactive peptide, has garnered renewed interest as a therapeutic target. Recent progress has been made in our understanding of how ET-1 pathways contribute to the breakdown of the glomerular filtration barrier. Targeting ET-1 pathways as a means of decreasing proteinuria is among the emerging therapies in IgAN.

This symposium summarizes current challenges and guideline recommendations in IgAN, examines our current understanding of the role ET-1 plays in damaging the glomerular filtration barrier, and explores the evolving treatment landscape in IgAN.

Support is provided by an educational grant from Travere Therapeutics, Inc.

Learning Objective(s)

  • Explain the significance of proteinuria in the progression of IgAN and the importance of reducing proteinuria to preserve kidney function
  • Describe the importance of ET-1 signaling in the breakdown of the glomerular filtration barrier and subsequent development of proteinuria
  • Discuss emerging therapeutic options in IgAN

Learning Pathway(s)

  • Glomerular Diseases